CD274 and neoplasm: Those tumours with high levels of PD-L1 on their surface and a lymphocytic infiltrate have been shown to respond well to anti-PD-1/anti-PD-L1 therapy, including melanoma, Hodgkin's lymphoma, non-small-cell lung, bladder, gastric, renal and ovarian cancers23.